nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylephrine—Epinephrine—Dipivefrin—glaucoma	0.202	0.427	CrCrCtD
Phenylephrine—Salbutamol—Levobunolol—glaucoma	0.135	0.287	CrCrCtD
Phenylephrine—Salbutamol—Carteolol—glaucoma	0.135	0.287	CrCrCtD
Phenylephrine—ADRA1A—Apraclonidine—glaucoma	0.0866	0.253	CbGbCtD
Phenylephrine—ADRA1A—Dipivefrin—glaucoma	0.0692	0.202	CbGbCtD
Phenylephrine—ADRA1D—Clonidine—glaucoma	0.0626	0.183	CbGbCtD
Phenylephrine—ADRA1B—Clonidine—glaucoma	0.0456	0.133	CbGbCtD
Phenylephrine—ADRA1A—Clonidine—glaucoma	0.036	0.105	CbGbCtD
Phenylephrine—CYP1A2—Betaxolol—glaucoma	0.0276	0.0806	CbGbCtD
Phenylephrine—CYP1A2—Clonidine—glaucoma	0.0151	0.0442	CbGbCtD
Phenylephrine—MAOA—Melatonin metabolism and effects—CYP1B1—glaucoma	0.000257	0.0199	CbGpPWpGaD
Phenylephrine—ADRA1D—GPCRs, Other—PTGFR—glaucoma	0.000244	0.0189	CbGpPWpGaD
Phenylephrine—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—glaucoma	0.000241	0.0187	CbGpPWpGaD
Phenylephrine—CYP1A2—Aflatoxin B1 metabolism—GSTM1—glaucoma	0.000236	0.0183	CbGpPWpGaD
Phenylephrine—MAOA—Oxidative Stress—SOD1—glaucoma	0.000223	0.0173	CbGpPWpGaD
Phenylephrine—MAOA—Melatonin metabolism and effects—EDN1—glaucoma	0.000208	0.0161	CbGpPWpGaD
Phenylephrine—ADRA1B—AMPK Signaling—RPTOR—glaucoma	0.000198	0.0153	CbGpPWpGaD
Phenylephrine—CYP1A2—Estrogen Receptor Pathway—CYP1B1—glaucoma	0.00018	0.0139	CbGpPWpGaD
Phenylephrine—ADRA1A—AMPK Signaling—RPTOR—glaucoma	0.000176	0.0136	CbGpPWpGaD
Phenylephrine—MAOA—Melatonin metabolism and effects—APOE—glaucoma	0.000169	0.0131	CbGpPWpGaD
Phenylephrine—ADRA1D—G alpha (q) signalling events—OPN4—glaucoma	0.000152	0.0118	CbGpPWpGaD
Phenylephrine—Dizziness—Levobunolol—glaucoma	0.000149	0.000867	CcSEcCtD
Phenylephrine—Dyspnoea—Apraclonidine—glaucoma	0.000149	0.000867	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.000149	0.000865	CcSEcCtD
Phenylephrine—Tremor—Pilocarpine—glaucoma	0.000149	0.000865	CcSEcCtD
Phenylephrine—Palpitations—Dorzolamide—glaucoma	0.000149	0.000863	CcSEcCtD
Phenylephrine—Bradycardia—Clonidine—glaucoma	0.000149	0.000862	CcSEcCtD
Phenylephrine—Pruritus—Latanoprost—glaucoma	0.000148	0.000861	CcSEcCtD
Phenylephrine—Rash—Diclofenamide—glaucoma	0.000148	0.000861	CcSEcCtD
Phenylephrine—Palpitations—Travoprost—glaucoma	0.000148	0.00086	CcSEcCtD
Phenylephrine—Loss of consciousness—Dorzolamide—glaucoma	0.000148	0.000859	CcSEcCtD
Phenylephrine—Shock—Acetazolamide—glaucoma	0.000147	0.000856	CcSEcCtD
Phenylephrine—Headache—Diclofenamide—glaucoma	0.000147	0.000855	CcSEcCtD
Phenylephrine—Palpitations—Brinzolamide—glaucoma	0.000146	0.000849	CcSEcCtD
Phenylephrine—Agitation—Pilocarpine—glaucoma	0.000146	0.000848	CcSEcCtD
Phenylephrine—Vomiting—Carbachol—glaucoma	0.000146	0.000847	CcSEcCtD
Phenylephrine—Hypertension—Dorzolamide—glaucoma	0.000145	0.000843	CcSEcCtD
Phenylephrine—Dyspnoea—Bimatoprost—glaucoma	0.000145	0.000841	CcSEcCtD
Phenylephrine—Rash—Carbachol—glaucoma	0.000145	0.00084	CcSEcCtD
Phenylephrine—Hypertension—Travoprost—glaucoma	0.000145	0.00084	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Apraclonidine—glaucoma	0.000145	0.00084	CcSEcCtD
Phenylephrine—Dermatitis—Carbachol—glaucoma	0.000145	0.000839	CcSEcCtD
Phenylephrine—Headache—Carbachol—glaucoma	0.000144	0.000834	CcSEcCtD
Phenylephrine—Chest pain—Dorzolamide—glaucoma	0.000143	0.000832	CcSEcCtD
Phenylephrine—Pain—Apraclonidine—glaucoma	0.000143	0.000832	CcSEcCtD
Phenylephrine—Hypertension—Brinzolamide—glaucoma	0.000143	0.000829	CcSEcCtD
Phenylephrine—Chest pain—Travoprost—glaucoma	0.000143	0.000828	CcSEcCtD
Phenylephrine—Syncope—Pilocarpine—glaucoma	0.000143	0.000828	CcSEcCtD
Phenylephrine—Nausea—Carteolol—glaucoma	0.000142	0.000825	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.000142	0.000822	CcSEcCtD
Phenylephrine—Headache—Levobunolol—glaucoma	0.000142	0.000822	CcSEcCtD
Phenylephrine—Shock—Brimonidine—glaucoma	0.000141	0.000821	CcSEcCtD
Phenylephrine—Nervous system disorder—Brimonidine—glaucoma	0.000141	0.000819	CcSEcCtD
Phenylephrine—Chest pain—Brinzolamide—glaucoma	0.000141	0.000818	CcSEcCtD
Phenylephrine—Palpitations—Pilocarpine—glaucoma	0.000141	0.000816	CcSEcCtD
Phenylephrine—Tachycardia—Brimonidine—glaucoma	0.00014	0.000815	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Bimatoprost—glaucoma	0.00014	0.000814	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.00014	0.000812	CcSEcCtD
Phenylephrine—Loss of consciousness—Pilocarpine—glaucoma	0.00014	0.000811	CcSEcCtD
Phenylephrine—Skin disorder—Brimonidine—glaucoma	0.00014	0.000811	CcSEcCtD
Phenylephrine—Nausea—Diclofenamide—glaucoma	0.00014	0.000811	CcSEcCtD
Phenylephrine—Acute coronary syndrome—Betaxolol—glaucoma	0.000139	0.00081	CcSEcCtD
Phenylephrine—Pain—Bimatoprost—glaucoma	0.000139	0.000806	CcSEcCtD
Phenylephrine—Myocardial infarction—Betaxolol—glaucoma	0.000139	0.000805	CcSEcCtD
Phenylephrine—CYP1A2—Estrogen metabolism—CYP1B1—glaucoma	0.000139	0.0107	CbGpPWpGaD
Phenylephrine—Dizziness—Latanoprost—glaucoma	0.000139	0.000804	CcSEcCtD
Phenylephrine—Vomiting—Methazolamide—glaucoma	0.000138	0.000799	CcSEcCtD
Phenylephrine—Hypertension—Pilocarpine—glaucoma	0.000137	0.000797	CcSEcCtD
Phenylephrine—ADRA1D—G alpha (q) signalling events—PTGFR—glaucoma	0.000137	0.0106	CbGpPWpGaD
Phenylephrine—Abdominal pain upper—Timolol—glaucoma	0.000137	0.000795	CcSEcCtD
Phenylephrine—Rash—Methazolamide—glaucoma	0.000136	0.000792	CcSEcCtD
Phenylephrine—Dermatitis—Methazolamide—glaucoma	0.000136	0.000792	CcSEcCtD
Phenylephrine—Nausea—Carbachol—glaucoma	0.000136	0.000791	CcSEcCtD
Phenylephrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.000136	0.0106	CbGpPWpGaD
Phenylephrine—Headache—Methazolamide—glaucoma	0.000136	0.000787	CcSEcCtD
Phenylephrine—Cardiac disorder—Clonidine—glaucoma	0.000135	0.000786	CcSEcCtD
Phenylephrine—Chest pain—Pilocarpine—glaucoma	0.000135	0.000786	CcSEcCtD
Phenylephrine—Shock—Dorzolamide—glaucoma	0.000135	0.000784	CcSEcCtD
Phenylephrine—ADRA1A—Endothelin Pathways—EDN1—glaucoma	0.000135	0.0104	CbGpPWpGaD
Phenylephrine—Paraesthesia—Acetazolamide—glaucoma	0.000135	0.000781	CcSEcCtD
Phenylephrine—Nausea—Levobunolol—glaucoma	0.000134	0.000779	CcSEcCtD
Phenylephrine—Nervous system disorder—Travoprost—glaucoma	0.000134	0.000779	CcSEcCtD
Phenylephrine—Tachycardia—Travoprost—glaucoma	0.000133	0.000775	CcSEcCtD
Phenylephrine—Skin disorder—Travoprost—glaucoma	0.000133	0.000771	CcSEcCtD
Phenylephrine—Hyperhidrosis—Dorzolamide—glaucoma	0.000133	0.000771	CcSEcCtD
Phenylephrine—Nervous system disorder—Brinzolamide—glaucoma	0.000132	0.000769	CcSEcCtD
Phenylephrine—Angiopathy—Clonidine—glaucoma	0.000132	0.000768	CcSEcCtD
Phenylephrine—Rash—Latanoprost—glaucoma	0.000132	0.000767	CcSEcCtD
Phenylephrine—Dermatitis—Latanoprost—glaucoma	0.000132	0.000766	CcSEcCtD
Phenylephrine—Tachycardia—Brinzolamide—glaucoma	0.000132	0.000765	CcSEcCtD
Phenylephrine—Mediastinal disorder—Clonidine—glaucoma	0.000131	0.000763	CcSEcCtD
Phenylephrine—Headache—Latanoprost—glaucoma	0.000131	0.000762	CcSEcCtD
Phenylephrine—Skin disorder—Brinzolamide—glaucoma	0.000131	0.000761	CcSEcCtD
Phenylephrine—Arrhythmia—Clonidine—glaucoma	0.00013	0.000757	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000129	0.000751	CcSEcCtD
Phenylephrine—Bradycardia—Betaxolol—glaucoma	0.000129	0.000751	CcSEcCtD
Phenylephrine—Paraesthesia—Brimonidine—glaucoma	0.000129	0.00075	CcSEcCtD
Phenylephrine—ADRA1D—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.000129	0.00998	CbGpPWpGaD
Phenylephrine—Nausea—Methazolamide—glaucoma	0.000129	0.000746	CcSEcCtD
Phenylephrine—Dyspnoea—Brimonidine—glaucoma	0.000128	0.000744	CcSEcCtD
Phenylephrine—Mental disorder—Clonidine—glaucoma	0.000128	0.000742	CcSEcCtD
Phenylephrine—Shock—Pilocarpine—glaucoma	0.000128	0.000741	CcSEcCtD
Phenylephrine—Tachycardia—Pilocarpine—glaucoma	0.000127	0.000735	CcSEcCtD
Phenylephrine—ADRA1B—G alpha (q) signalling events—OPN4—glaucoma	0.000126	0.0098	CbGpPWpGaD
Phenylephrine—Hyperhidrosis—Pilocarpine—glaucoma	0.000125	0.000728	CcSEcCtD
Phenylephrine—Tension—Clonidine—glaucoma	0.000125	0.000723	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Brimonidine—glaucoma	0.000124	0.000721	CcSEcCtD
Phenylephrine—Hypersensitivity—Apraclonidine—glaucoma	0.000123	0.000716	CcSEcCtD
Phenylephrine—Nervousness—Clonidine—glaucoma	0.000123	0.000716	CcSEcCtD
Phenylephrine—Paraesthesia—Dorzolamide—glaucoma	0.000123	0.000716	CcSEcCtD
Phenylephrine—ADRA1D—GPCRs, Other—SMO—glaucoma	0.000123	0.00954	CbGpPWpGaD
Phenylephrine—Pain—Brimonidine—glaucoma	0.000123	0.000714	CcSEcCtD
Phenylephrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.000123	0.00951	CbGpPWpGaD
Phenylephrine—CYP1A2—Tamoxifen metabolism—CYP1B1—glaucoma	0.000123	0.0095	CbGpPWpGaD
Phenylephrine—Dyspnoea—Dorzolamide—glaucoma	0.000122	0.000711	CcSEcCtD
Phenylephrine—Visual impairment—Betaxolol—glaucoma	0.000122	0.00071	CcSEcCtD
Phenylephrine—Dyspnoea—Travoprost—glaucoma	0.000122	0.000708	CcSEcCtD
Phenylephrine—Paraesthesia—Brinzolamide—glaucoma	0.000121	0.000704	CcSEcCtD
Phenylephrine—Dyspnoea—Brinzolamide—glaucoma	0.00012	0.000699	CcSEcCtD
Phenylephrine—Vision blurred—Clonidine—glaucoma	0.00012	0.000695	CcSEcCtD
Phenylephrine—Urticaria—Acetazolamide—glaucoma	0.000119	0.000691	CcSEcCtD
Phenylephrine—Tremor—Clonidine—glaucoma	0.000119	0.000691	CcSEcCtD
Phenylephrine—Pruritus—Apraclonidine—glaucoma	0.000119	0.000688	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Travoprost—glaucoma	0.000118	0.000685	CcSEcCtD
Phenylephrine—Cardiac disorder—Betaxolol—glaucoma	0.000118	0.000684	CcSEcCtD
Phenylephrine—ADRA1D—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000118	0.00913	CbGpPWpGaD
Phenylephrine—Pain—Dorzolamide—glaucoma	0.000117	0.000682	CcSEcCtD
Phenylephrine—Pain—Travoprost—glaucoma	0.000117	0.000679	CcSEcCtD
Phenylephrine—Agitation—Clonidine—glaucoma	0.000117	0.000677	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000117	0.000677	CcSEcCtD
Phenylephrine—Paraesthesia—Pilocarpine—glaucoma	0.000117	0.000676	CcSEcCtD
Phenylephrine—MAOA—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000116	0.00902	CbGpPWpGaD
Phenylephrine—Dyspnoea—Pilocarpine—glaucoma	0.000116	0.000672	CcSEcCtD
Phenylephrine—Pain—Brinzolamide—glaucoma	0.000115	0.00067	CcSEcCtD
Phenylephrine—Angiopathy—Betaxolol—glaucoma	0.000115	0.000669	CcSEcCtD
Phenylephrine—Pruritus—Bimatoprost—glaucoma	0.000115	0.000667	CcSEcCtD
Phenylephrine—Immune system disorder—Betaxolol—glaucoma	0.000115	0.000666	CcSEcCtD
Phenylephrine—Mediastinal disorder—Betaxolol—glaucoma	0.000114	0.000664	CcSEcCtD
Phenylephrine—Syncope—Clonidine—glaucoma	0.000114	0.000661	CcSEcCtD
Phenylephrine—ADRA1B—G alpha (q) signalling events—PTGFR—glaucoma	0.000114	0.00882	CbGpPWpGaD
Phenylephrine—Arrhythmia—Betaxolol—glaucoma	0.000113	0.000659	CcSEcCtD
Phenylephrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.000113	0.00876	CbGpPWpGaD
Phenylephrine—ADRA1A—G alpha (q) signalling events—OPN4—glaucoma	0.000112	0.0087	CbGpPWpGaD
Phenylephrine—Palpitations—Clonidine—glaucoma	0.000112	0.000651	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000112	0.00065	CcSEcCtD
Phenylephrine—Loss of consciousness—Clonidine—glaucoma	0.000112	0.000648	CcSEcCtD
Phenylephrine—Mental disorder—Betaxolol—glaucoma	0.000111	0.000646	CcSEcCtD
Phenylephrine—Pain—Pilocarpine—glaucoma	0.000111	0.000644	CcSEcCtD
Phenylephrine—CYP1A2—Estrogen metabolism—GSTM1—glaucoma	0.000111	0.00859	CbGpPWpGaD
Phenylephrine—Dizziness—Apraclonidine—glaucoma	0.000111	0.000643	CcSEcCtD
Phenylephrine—Urticaria—Dorzolamide—glaucoma	0.000109	0.000633	CcSEcCtD
Phenylephrine—Tension—Betaxolol—glaucoma	0.000108	0.00063	CcSEcCtD
Phenylephrine—Dysgeusia—Betaxolol—glaucoma	0.000108	0.000628	CcSEcCtD
Phenylephrine—Chest pain—Clonidine—glaucoma	0.000108	0.000628	CcSEcCtD
Phenylephrine—MAOA—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.000108	0.00837	CbGpPWpGaD
Phenylephrine—Dizziness—Bimatoprost—glaucoma	0.000107	0.000623	CcSEcCtD
Phenylephrine—Nervousness—Betaxolol—glaucoma	0.000107	0.000623	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000107	0.000623	CcSEcCtD
Phenylephrine—Urticaria—Brinzolamide—glaucoma	0.000107	0.000623	CcSEcCtD
Phenylephrine—ADRA1B—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.000107	0.00828	CbGpPWpGaD
Phenylephrine—Vomiting—Apraclonidine—glaucoma	0.000107	0.000618	CcSEcCtD
Phenylephrine—ADRA1D—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.000106	0.00822	CbGpPWpGaD
Phenylephrine—Hypersensitivity—Brimonidine—glaucoma	0.000106	0.000615	CcSEcCtD
Phenylephrine—Bradycardia—Timolol—glaucoma	0.000106	0.000613	CcSEcCtD
Phenylephrine—Dermatitis—Apraclonidine—glaucoma	0.000106	0.000613	CcSEcCtD
Phenylephrine—Headache—Apraclonidine—glaucoma	0.000105	0.000609	CcSEcCtD
Phenylephrine—MAOA—SIDS Susceptibility Pathways—HDAC9—glaucoma	0.000105	0.00812	CbGpPWpGaD
Phenylephrine—Vision blurred—Betaxolol—glaucoma	0.000104	0.000605	CcSEcCtD
Phenylephrine—Tremor—Betaxolol—glaucoma	0.000104	0.000601	CcSEcCtD
Phenylephrine—Rash—Bimatoprost—glaucoma	0.000102	0.000594	CcSEcCtD
Phenylephrine—Dermatitis—Bimatoprost—glaucoma	0.000102	0.000594	CcSEcCtD
Phenylephrine—Shock—Clonidine—glaucoma	0.000102	0.000592	CcSEcCtD
Phenylephrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.000102	0.00789	CbGpPWpGaD
Phenylephrine—Pruritus—Brimonidine—glaucoma	0.000102	0.000591	CcSEcCtD
Phenylephrine—Headache—Bimatoprost—glaucoma	0.000102	0.000591	CcSEcCtD
Phenylephrine—Nervous system disorder—Clonidine—glaucoma	0.000102	0.00059	CcSEcCtD
Phenylephrine—Hypersensitivity—Dorzolamide—glaucoma	0.000101	0.000587	CcSEcCtD
Phenylephrine—Tachycardia—Clonidine—glaucoma	0.000101	0.000587	CcSEcCtD
Phenylephrine—ADRA1A—G alpha (q) signalling events—PTGFR—glaucoma	0.000101	0.00784	CbGpPWpGaD
Phenylephrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.000101	0.00782	CbGpPWpGaD
Phenylephrine—Hypersensitivity—Travoprost—glaucoma	0.000101	0.000585	CcSEcCtD
Phenylephrine—Skin disorder—Clonidine—glaucoma	0.000101	0.000584	CcSEcCtD
Phenylephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.0001	0.00778	CbGpPWpGaD
Phenylephrine—Hyperhidrosis—Clonidine—glaucoma	0.0001	0.000582	CcSEcCtD
Phenylephrine—Visual impairment—Timolol—glaucoma	0.0001	0.00058	CcSEcCtD
Phenylephrine—Nausea—Apraclonidine—glaucoma	9.95e-05	0.000578	CcSEcCtD
Phenylephrine—Hypersensitivity—Brinzolamide—glaucoma	9.95e-05	0.000578	CcSEcCtD
Phenylephrine—Syncope—Betaxolol—glaucoma	9.91e-05	0.000576	CcSEcCtD
Phenylephrine—Dizziness—Acetazolamide—glaucoma	9.91e-05	0.000575	CcSEcCtD
Phenylephrine—ADRA1B—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	9.77e-05	0.00757	CbGpPWpGaD
Phenylephrine—Palpitations—Betaxolol—glaucoma	9.77e-05	0.000567	CcSEcCtD
Phenylephrine—Pruritus—Dorzolamide—glaucoma	9.72e-05	0.000564	CcSEcCtD
Phenylephrine—Loss of consciousness—Betaxolol—glaucoma	9.72e-05	0.000564	CcSEcCtD
Phenylephrine—Pruritus—Travoprost—glaucoma	9.68e-05	0.000562	CcSEcCtD
Phenylephrine—Nausea—Bimatoprost—glaucoma	9.65e-05	0.00056	CcSEcCtD
Phenylephrine—Cardiac disorder—Timolol—glaucoma	9.63e-05	0.000559	CcSEcCtD
Phenylephrine—Hypersensitivity—Pilocarpine—glaucoma	9.56e-05	0.000555	CcSEcCtD
Phenylephrine—Pruritus—Brinzolamide—glaucoma	9.55e-05	0.000555	CcSEcCtD
Phenylephrine—Vomiting—Acetazolamide—glaucoma	9.53e-05	0.000553	CcSEcCtD
Phenylephrine—Dizziness—Brimonidine—glaucoma	9.51e-05	0.000552	CcSEcCtD
Phenylephrine—ADRA1A—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	9.49e-05	0.00736	CbGpPWpGaD
Phenylephrine—CYP1A2—Melatonin metabolism and effects—CYP1B1—glaucoma	9.47e-05	0.00734	CbGpPWpGaD
Phenylephrine—Angiopathy—Timolol—glaucoma	9.41e-05	0.000546	CcSEcCtD
Phenylephrine—Chest pain—Betaxolol—glaucoma	9.41e-05	0.000546	CcSEcCtD
Phenylephrine—Headache—Acetazolamide—glaucoma	9.39e-05	0.000545	CcSEcCtD
Phenylephrine—Immune system disorder—Timolol—glaucoma	9.37e-05	0.000544	CcSEcCtD
Phenylephrine—Mediastinal disorder—Timolol—glaucoma	9.35e-05	0.000543	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	9.35e-05	0.000543	CcSEcCtD
Phenylephrine—Paraesthesia—Clonidine—glaucoma	9.31e-05	0.00054	CcSEcCtD
Phenylephrine—Arrhythmia—Timolol—glaucoma	9.27e-05	0.000538	CcSEcCtD
Phenylephrine—Dyspnoea—Clonidine—glaucoma	9.24e-05	0.000536	CcSEcCtD
Phenylephrine—Pruritus—Pilocarpine—glaucoma	9.18e-05	0.000533	CcSEcCtD
Phenylephrine—Mental disorder—Timolol—glaucoma	9.09e-05	0.000528	CcSEcCtD
Phenylephrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	9.08e-05	0.00704	CbGpPWpGaD
Phenylephrine—Dizziness—Dorzolamide—glaucoma	9.08e-05	0.000527	CcSEcCtD
Phenylephrine—Rash—Brimonidine—glaucoma	9.07e-05	0.000526	CcSEcCtD
Phenylephrine—Dermatitis—Brimonidine—glaucoma	9.06e-05	0.000526	CcSEcCtD
Phenylephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	9.04e-05	0.00701	CbGpPWpGaD
Phenylephrine—Dizziness—Travoprost—glaucoma	9.04e-05	0.000525	CcSEcCtD
Phenylephrine—Headache—Brimonidine—glaucoma	9.01e-05	0.000523	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Clonidine—glaucoma	8.95e-05	0.000519	CcSEcCtD
Phenylephrine—Dizziness—Brinzolamide—glaucoma	8.93e-05	0.000518	CcSEcCtD
Phenylephrine—Nausea—Acetazolamide—glaucoma	8.9e-05	0.000517	CcSEcCtD
Phenylephrine—Shock—Betaxolol—glaucoma	8.88e-05	0.000515	CcSEcCtD
Phenylephrine—Tension—Timolol—glaucoma	8.86e-05	0.000514	CcSEcCtD
Phenylephrine—Pain—Clonidine—glaucoma	8.86e-05	0.000514	CcSEcCtD
Phenylephrine—Nervous system disorder—Betaxolol—glaucoma	8.85e-05	0.000514	CcSEcCtD
Phenylephrine—Dysgeusia—Timolol—glaucoma	8.84e-05	0.000513	CcSEcCtD
Phenylephrine—Tachycardia—Betaxolol—glaucoma	8.81e-05	0.000511	CcSEcCtD
Phenylephrine—ADRA1B—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	8.8e-05	0.00682	CbGpPWpGaD
Phenylephrine—Nervousness—Timolol—glaucoma	8.77e-05	0.000509	CcSEcCtD
Phenylephrine—Skin disorder—Betaxolol—glaucoma	8.76e-05	0.000509	CcSEcCtD
Phenylephrine—Vomiting—Dorzolamide—glaucoma	8.73e-05	0.000507	CcSEcCtD
Phenylephrine—Hyperhidrosis—Betaxolol—glaucoma	8.72e-05	0.000506	CcSEcCtD
Phenylephrine—ADRA1A—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	8.68e-05	0.00673	CbGpPWpGaD
Phenylephrine—Rash—Dorzolamide—glaucoma	8.66e-05	0.000503	CcSEcCtD
Phenylephrine—Dermatitis—Dorzolamide—glaucoma	8.65e-05	0.000502	CcSEcCtD
Phenylephrine—Rash—Travoprost—glaucoma	8.62e-05	0.000501	CcSEcCtD
Phenylephrine—Dermatitis—Travoprost—glaucoma	8.61e-05	0.0005	CcSEcCtD
Phenylephrine—Headache—Dorzolamide—glaucoma	8.6e-05	0.000499	CcSEcCtD
Phenylephrine—Vomiting—Brinzolamide—glaucoma	8.59e-05	0.000498	CcSEcCtD
Phenylephrine—Dizziness—Pilocarpine—glaucoma	8.58e-05	0.000498	CcSEcCtD
Phenylephrine—Headache—Travoprost—glaucoma	8.57e-05	0.000497	CcSEcCtD
Phenylephrine—Nausea—Brimonidine—glaucoma	8.54e-05	0.000496	CcSEcCtD
Phenylephrine—Rash—Brinzolamide—glaucoma	8.51e-05	0.000494	CcSEcCtD
Phenylephrine—Vision blurred—Timolol—glaucoma	8.51e-05	0.000494	CcSEcCtD
Phenylephrine—Dermatitis—Brinzolamide—glaucoma	8.51e-05	0.000494	CcSEcCtD
Phenylephrine—Headache—Brinzolamide—glaucoma	8.46e-05	0.000491	CcSEcCtD
Phenylephrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	8.37e-05	0.00649	CbGpPWpGaD
Phenylephrine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	8.34e-05	0.00646	CbGpPWpGaD
Phenylephrine—MAOA—Neuronal System—SLC6A13—glaucoma	8.27e-05	0.00641	CbGpPWpGaD
Phenylephrine—Vomiting—Pilocarpine—glaucoma	8.25e-05	0.000479	CcSEcCtD
Phenylephrine—Urticaria—Clonidine—glaucoma	8.23e-05	0.000478	CcSEcCtD
Phenylephrine—ADRA1A—Endothelin Pathways—NOS3—glaucoma	8.2e-05	0.00636	CbGpPWpGaD
Phenylephrine—Rash—Pilocarpine—glaucoma	8.18e-05	0.000475	CcSEcCtD
Phenylephrine—Dermatitis—Pilocarpine—glaucoma	8.18e-05	0.000475	CcSEcCtD
Phenylephrine—Nausea—Dorzolamide—glaucoma	8.16e-05	0.000474	CcSEcCtD
Phenylephrine—Headache—Pilocarpine—glaucoma	8.13e-05	0.000472	CcSEcCtD
Phenylephrine—Nausea—Travoprost—glaucoma	8.12e-05	0.000472	CcSEcCtD
Phenylephrine—Paraesthesia—Betaxolol—glaucoma	8.1e-05	0.00047	CcSEcCtD
Phenylephrine—Syncope—Timolol—glaucoma	8.1e-05	0.00047	CcSEcCtD
Phenylephrine—Dyspnoea—Betaxolol—glaucoma	8.04e-05	0.000467	CcSEcCtD
Phenylephrine—Nausea—Brinzolamide—glaucoma	8.02e-05	0.000466	CcSEcCtD
Phenylephrine—Palpitations—Timolol—glaucoma	7.98e-05	0.000463	CcSEcCtD
Phenylephrine—Loss of consciousness—Timolol—glaucoma	7.94e-05	0.000461	CcSEcCtD
Phenylephrine—MAOA—Transmission across Chemical Synapses—SLC6A1—glaucoma	7.9e-05	0.00612	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	7.82e-05	0.00606	CbGpPWpGaD
Phenylephrine—Hypertension—Timolol—glaucoma	7.8e-05	0.000453	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Betaxolol—glaucoma	7.79e-05	0.000452	CcSEcCtD
Phenylephrine—MAOA—Biological oxidations—GSTT1—glaucoma	7.76e-05	0.00601	CbGpPWpGaD
Phenylephrine—Pain—Betaxolol—glaucoma	7.72e-05	0.000448	CcSEcCtD
Phenylephrine—Nausea—Pilocarpine—glaucoma	7.71e-05	0.000448	CcSEcCtD
Phenylephrine—Chest pain—Timolol—glaucoma	7.69e-05	0.000446	CcSEcCtD
Phenylephrine—ADRA1D—GPCR ligand binding—OPN4—glaucoma	7.68e-05	0.00595	CbGpPWpGaD
Phenylephrine—CYP1A2—Melatonin metabolism and effects—EDN1—glaucoma	7.66e-05	0.00594	CbGpPWpGaD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	7.64e-05	0.000443	CcSEcCtD
Phenylephrine—Hypersensitivity—Clonidine—glaucoma	7.64e-05	0.000443	CcSEcCtD
Phenylephrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	7.54e-05	0.00584	CbGpPWpGaD
Phenylephrine—MAOA—SIDS Susceptibility Pathways—NTRK2—glaucoma	7.5e-05	0.00581	CbGpPWpGaD
Phenylephrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	7.44e-05	0.00576	CbGpPWpGaD
Phenylephrine—Pruritus—Clonidine—glaucoma	7.33e-05	0.000426	CcSEcCtD
Phenylephrine—Shock—Timolol—glaucoma	7.25e-05	0.000421	CcSEcCtD
Phenylephrine—Nervous system disorder—Timolol—glaucoma	7.23e-05	0.00042	CcSEcCtD
Phenylephrine—Urticaria—Betaxolol—glaucoma	7.17e-05	0.000416	CcSEcCtD
Phenylephrine—Skin disorder—Timolol—glaucoma	7.16e-05	0.000416	CcSEcCtD
Phenylephrine—Hyperhidrosis—Timolol—glaucoma	7.13e-05	0.000414	CcSEcCtD
Phenylephrine—ADRA1D—GPCR ligand binding—PTGFR—glaucoma	6.92e-05	0.00536	CbGpPWpGaD
Phenylephrine—Dizziness—Clonidine—glaucoma	6.85e-05	0.000398	CcSEcCtD
Phenylephrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	6.7e-05	0.00519	CbGpPWpGaD
Phenylephrine—Hypersensitivity—Betaxolol—glaucoma	6.65e-05	0.000386	CcSEcCtD
Phenylephrine—Paraesthesia—Timolol—glaucoma	6.62e-05	0.000384	CcSEcCtD
Phenylephrine—Vomiting—Clonidine—glaucoma	6.59e-05	0.000383	CcSEcCtD
Phenylephrine—Dyspnoea—Timolol—glaucoma	6.57e-05	0.000381	CcSEcCtD
Phenylephrine—CYP1A2—Tryptophan metabolism—CYP1B1—glaucoma	6.55e-05	0.00507	CbGpPWpGaD
Phenylephrine—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—glaucoma	6.55e-05	0.00507	CbGpPWpGaD
Phenylephrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—glaucoma	6.55e-05	0.00507	CbGpPWpGaD
Phenylephrine—Rash—Clonidine—glaucoma	6.53e-05	0.000379	CcSEcCtD
Phenylephrine—Dermatitis—Clonidine—glaucoma	6.53e-05	0.000379	CcSEcCtD
Phenylephrine—Headache—Clonidine—glaucoma	6.49e-05	0.000377	CcSEcCtD
Phenylephrine—Pruritus—Betaxolol—glaucoma	6.38e-05	0.000371	CcSEcCtD
Phenylephrine—ADRA1B—GPCR ligand binding—OPN4—glaucoma	6.38e-05	0.00494	CbGpPWpGaD
Phenylephrine—Gastrointestinal disorder—Timolol—glaucoma	6.36e-05	0.000369	CcSEcCtD
Phenylephrine—Pain—Timolol—glaucoma	6.3e-05	0.000366	CcSEcCtD
Phenylephrine—CYP1A2—Melatonin metabolism and effects—APOE—glaucoma	6.23e-05	0.00483	CbGpPWpGaD
Phenylephrine—MAOA—Biological oxidations—CYP1B1—glaucoma	6.18e-05	0.00479	CbGpPWpGaD
Phenylephrine—Nausea—Clonidine—glaucoma	6.16e-05	0.000357	CcSEcCtD
Phenylephrine—CYP1A2—Arachidonic acid metabolism—CYP1B1—glaucoma	6.12e-05	0.00475	CbGpPWpGaD
Phenylephrine—MAOA—Neuronal System—SLC6A1—glaucoma	6.05e-05	0.00469	CbGpPWpGaD
Phenylephrine—Dizziness—Betaxolol—glaucoma	5.97e-05	0.000346	CcSEcCtD
Phenylephrine—Urticaria—Timolol—glaucoma	5.86e-05	0.00034	CcSEcCtD
Phenylephrine—ADRA1B—LPA receptor mediated events—MMP2—glaucoma	5.8e-05	0.0045	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR ligand binding—PTGFR—glaucoma	5.74e-05	0.00445	CbGpPWpGaD
Phenylephrine—Vomiting—Betaxolol—glaucoma	5.74e-05	0.000333	CcSEcCtD
Phenylephrine—Rash—Betaxolol—glaucoma	5.69e-05	0.00033	CcSEcCtD
Phenylephrine—Dermatitis—Betaxolol—glaucoma	5.68e-05	0.00033	CcSEcCtD
Phenylephrine—ADRA1A—GPCR ligand binding—OPN4—glaucoma	5.66e-05	0.00439	CbGpPWpGaD
Phenylephrine—Headache—Betaxolol—glaucoma	5.65e-05	0.000328	CcSEcCtD
Phenylephrine—MAOA—SIDS Susceptibility Pathways—BDNF—glaucoma	5.6e-05	0.00434	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—CA5A—glaucoma	5.44e-05	0.00421	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—NARFL—glaucoma	5.44e-05	0.00421	CbGpPWpGaD
Phenylephrine—Hypersensitivity—Timolol—glaucoma	5.43e-05	0.000315	CcSEcCtD
Phenylephrine—MAOA—SIDS Susceptibility Pathways—IL1A—glaucoma	5.37e-05	0.00416	CbGpPWpGaD
Phenylephrine—Nausea—Betaxolol—glaucoma	5.36e-05	0.000311	CcSEcCtD
Phenylephrine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	5.29e-05	0.0041	CbGpPWpGaD
Phenylephrine—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—glaucoma	5.22e-05	0.00405	CbGpPWpGaD
Phenylephrine—Pruritus—Timolol—glaucoma	5.21e-05	0.000303	CcSEcCtD
Phenylephrine—ADRA1A—GPCR ligand binding—PTGFR—glaucoma	5.1e-05	0.00395	CbGpPWpGaD
Phenylephrine—MAOA—SIDS Susceptibility Pathways—NGF—glaucoma	4.97e-05	0.00385	CbGpPWpGaD
Phenylephrine—MAOA—SIDS Susceptibility Pathways—NR3C1—glaucoma	4.94e-05	0.00383	CbGpPWpGaD
Phenylephrine—MAOA—Biological oxidations—GSTM1—glaucoma	4.94e-05	0.00383	CbGpPWpGaD
Phenylephrine—CYP1A2—Phase II conjugation—GSTT1—glaucoma	4.89e-05	0.00379	CbGpPWpGaD
Phenylephrine—Dizziness—Timolol—glaucoma	4.87e-05	0.000283	CcSEcCtD
Phenylephrine—Vomiting—Timolol—glaucoma	4.69e-05	0.000272	CcSEcCtD
Phenylephrine—Rash—Timolol—glaucoma	4.65e-05	0.00027	CcSEcCtD
Phenylephrine—Dermatitis—Timolol—glaucoma	4.64e-05	0.00027	CcSEcCtD
Phenylephrine—Headache—Timolol—glaucoma	4.62e-05	0.000268	CcSEcCtD
Phenylephrine—ADRA1D—G alpha (q) signalling events—EDN1—glaucoma	4.56e-05	0.00353	CbGpPWpGaD
Phenylephrine—Nausea—Timolol—glaucoma	4.38e-05	0.000254	CcSEcCtD
Phenylephrine—ADRA1B—LPA receptor mediated events—MMP9—glaucoma	4.36e-05	0.00338	CbGpPWpGaD
Phenylephrine—ADRA1D—GPCR downstream signaling—OPN4—glaucoma	4.34e-05	0.00336	CbGpPWpGaD
Phenylephrine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	4.29e-05	0.00333	CbGpPWpGaD
Phenylephrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	4.08e-05	0.00316	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling by GPCR—OPN4—glaucoma	3.94e-05	0.00306	CbGpPWpGaD
Phenylephrine—ADRA1D—GPCR downstream signaling—PTGFR—glaucoma	3.91e-05	0.00303	CbGpPWpGaD
Phenylephrine—ADRA1B—G alpha (q) signalling events—EDN1—glaucoma	3.78e-05	0.00293	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR downstream signaling—OPN4—glaucoma	3.6e-05	0.00279	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling by GPCR—PTGFR—glaucoma	3.55e-05	0.00275	CbGpPWpGaD
Phenylephrine—ADRA1D—GPCR ligand binding—SMO—glaucoma	3.49e-05	0.0027	CbGpPWpGaD
Phenylephrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	3.38e-05	0.00262	CbGpPWpGaD
Phenylephrine—ADRA1A—G alpha (q) signalling events—EDN1—glaucoma	3.36e-05	0.00261	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—LRP12—glaucoma	3.36e-05	0.0026	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—OPN4—glaucoma	3.27e-05	0.00254	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR downstream signaling—PTGFR—glaucoma	3.24e-05	0.00251	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR downstream signaling—OPN4—glaucoma	3.2e-05	0.00248	CbGpPWpGaD
Phenylephrine—CYP1A2—Phase II conjugation—GSTM1—glaucoma	3.11e-05	0.00241	CbGpPWpGaD
Phenylephrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	3.02e-05	0.00234	CbGpPWpGaD
Phenylephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	3.01e-05	0.00233	CbGpPWpGaD
Phenylephrine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—glaucoma	2.95e-05	0.00229	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—PTGFR—glaucoma	2.95e-05	0.00228	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—OPN4—glaucoma	2.91e-05	0.00225	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR ligand binding—SMO—glaucoma	2.89e-05	0.00224	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR downstream signaling—PTGFR—glaucoma	2.88e-05	0.00223	CbGpPWpGaD
Phenylephrine—CYP1A2—Biological oxidations—GSTT1—glaucoma	2.86e-05	0.00222	CbGpPWpGaD
Phenylephrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—glaucoma	2.79e-05	0.00217	CbGpPWpGaD
Phenylephrine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	2.79e-05	0.00217	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—LRP12—glaucoma	2.79e-05	0.00216	CbGpPWpGaD
Phenylephrine—ADRA1B—AMPK Signaling—TP53—glaucoma	2.79e-05	0.00216	CbGpPWpGaD
Phenylephrine—CYP1A2—Arachidonic acid metabolism—PTGS2—glaucoma	2.76e-05	0.00214	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—CA1—glaucoma	2.65e-05	0.00206	CbGpPWpGaD
Phenylephrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	2.64e-05	0.00204	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—PTGFR—glaucoma	2.62e-05	0.00203	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR ligand binding—SMO—glaucoma	2.57e-05	0.00199	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—CTSA—glaucoma	2.57e-05	0.00199	CbGpPWpGaD
Phenylephrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	2.51e-05	0.00194	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—LRP12—glaucoma	2.48e-05	0.00192	CbGpPWpGaD
Phenylephrine—ADRA1A—AMPK Signaling—TP53—glaucoma	2.48e-05	0.00192	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—CA2—glaucoma	2.43e-05	0.00188	CbGpPWpGaD
Phenylephrine—MAOA—SIDS Susceptibility Pathways—VEGFA—glaucoma	2.37e-05	0.00184	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—OPN4—glaucoma	2.33e-05	0.0018	CbGpPWpGaD
Phenylephrine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	2.32e-05	0.0018	CbGpPWpGaD
Phenylephrine—ADRA1D—GPCR ligand binding—EDN1—glaucoma	2.3e-05	0.00178	CbGpPWpGaD
Phenylephrine—CYP1A2—Biological oxidations—CYP1B1—glaucoma	2.28e-05	0.00177	CbGpPWpGaD
Phenylephrine—CYP1A2—Metapathway biotransformation—CYP1B1—glaucoma	2.25e-05	0.00174	CbGpPWpGaD
Phenylephrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	2.23e-05	0.00173	CbGpPWpGaD
Phenylephrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	2.19e-05	0.0017	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—HEYL—glaucoma	2.17e-05	0.00168	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	2.13e-05	0.00165	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—PTGFR—glaucoma	2.1e-05	0.00163	CbGpPWpGaD
Phenylephrine—MAOA—SIDS Susceptibility Pathways—TNF—glaucoma	2.03e-05	0.00158	CbGpPWpGaD
Phenylephrine—ADRA1D—GPCR ligand binding—C3—glaucoma	2.01e-05	0.00156	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—NARFL—glaucoma	2e-05	0.00155	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CA5A—glaucoma	2e-05	0.00155	CbGpPWpGaD
Phenylephrine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—glaucoma	1.99e-05	0.00154	CbGpPWpGaD
Phenylephrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—glaucoma	1.99e-05	0.00154	CbGpPWpGaD
Phenylephrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	1.94e-05	0.00151	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—OPN4—glaucoma	1.93e-05	0.0015	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR ligand binding—EDN1—glaucoma	1.91e-05	0.00148	CbGpPWpGaD
Phenylephrine—CYP1A2—Biological oxidations—GSTM1—glaucoma	1.82e-05	0.00141	CbGpPWpGaD
Phenylephrine—CYP1A2—Metapathway biotransformation—GSTM1—glaucoma	1.8e-05	0.00139	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—HEYL—glaucoma	1.8e-05	0.00139	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling by GPCR—SMO—glaucoma	1.79e-05	0.00139	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—PTGFR—glaucoma	1.74e-05	0.00135	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—OPN4—glaucoma	1.72e-05	0.00133	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—TXN—glaucoma	1.71e-05	0.00133	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR ligand binding—EDN1—glaucoma	1.7e-05	0.00131	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR ligand binding—C3—glaucoma	1.67e-05	0.00129	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—RPTOR—glaucoma	1.64e-05	0.00127	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—HEYL—glaucoma	1.6e-05	0.00124	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—NCK2—glaucoma	1.59e-05	0.00123	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—PTGFR—glaucoma	1.55e-05	0.0012	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—SMO—glaucoma	1.49e-05	0.00115	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR ligand binding—C3—glaucoma	1.48e-05	0.00115	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—RPTOR—glaucoma	1.36e-05	0.00106	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—HDAC9—glaucoma	1.35e-05	0.00105	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—GSTT1—glaucoma	1.33e-05	0.00103	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—SMO—glaucoma	1.32e-05	0.00102	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—NCK2—glaucoma	1.32e-05	0.00102	CbGpPWpGaD
Phenylephrine—ADRA1D—GPCR downstream signaling—EDN1—glaucoma	1.3e-05	0.00101	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—RPTOR—glaucoma	1.21e-05	0.000938	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling by GPCR—EDN1—glaucoma	1.18e-05	0.000915	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—NCK2—glaucoma	1.17e-05	0.000908	CbGpPWpGaD
Phenylephrine—ADRA1D—GPCR downstream signaling—C3—glaucoma	1.14e-05	0.00088	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—HDAC9—glaucoma	1.12e-05	0.000869	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR downstream signaling—EDN1—glaucoma	1.08e-05	0.000836	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—SMO—glaucoma	1.06e-05	0.000819	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—ABCA1—glaucoma	1.06e-05	0.000819	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—CYP1B1—glaucoma	1.06e-05	0.000819	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling by GPCR—C3—glaucoma	1.03e-05	0.000799	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—HDAC9—glaucoma	9.96e-06	0.000772	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—EDN1—glaucoma	9.79e-06	0.000759	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CA1—glaucoma	9.79e-06	0.000759	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—NTRK2—glaucoma	9.67e-06	0.000749	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR downstream signaling—EDN1—glaucoma	9.58e-06	0.000742	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CTSA—glaucoma	9.48e-06	0.000735	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR downstream signaling—C3—glaucoma	9.42e-06	0.00073	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CA2—glaucoma	8.95e-06	0.000694	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—SMO—glaucoma	8.78e-06	0.00068	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	8.75e-06	0.000678	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	8.75e-06	0.000678	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—EDN1—glaucoma	8.7e-06	0.000674	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—C3—glaucoma	8.56e-06	0.000663	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—GSTM1—glaucoma	8.45e-06	0.000655	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR downstream signaling—C3—glaucoma	8.37e-06	0.000649	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—NGFR—glaucoma	8.3e-06	0.000643	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—NTRK2—glaucoma	8.03e-06	0.000622	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—NTRK1—glaucoma	7.88e-06	0.000611	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—SMO—glaucoma	7.79e-06	0.000604	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—C3—glaucoma	7.6e-06	0.000589	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—MTHFR—glaucoma	7.47e-06	0.000579	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—CDKN2B—glaucoma	7.26e-06	0.000563	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—NTRK2—glaucoma	7.13e-06	0.000553	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—EDN1—glaucoma	6.97e-06	0.00054	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—APOE—glaucoma	6.95e-06	0.000539	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—CAV1—glaucoma	6.89e-06	0.000534	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—NGFR—glaucoma	6.89e-06	0.000534	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—NTRK1—glaucoma	6.54e-06	0.000507	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—NGF—glaucoma	6.41e-06	0.000496	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—TXN—glaucoma	6.31e-06	0.000489	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—NGFR—glaucoma	6.12e-06	0.000474	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—C3—glaucoma	6.09e-06	0.000472	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—CDKN2B—glaucoma	6.03e-06	0.000467	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—NTRK1—glaucoma	5.81e-06	0.00045	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—EDN1—glaucoma	5.79e-06	0.000448	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—glaucoma	5.76e-06	0.000446	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	5.7e-06	0.000442	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—APOE—glaucoma	5.67e-06	0.000439	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—CAV1—glaucoma	5.62e-06	0.000435	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CDKN2B—glaucoma	5.36e-06	0.000415	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—FN1—glaucoma	5.35e-06	0.000414	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—NGF—glaucoma	5.32e-06	0.000412	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—BAD—glaucoma	5.28e-06	0.000409	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—NOS3—glaucoma	5.21e-06	0.000404	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—EDN1—glaucoma	5.14e-06	0.000398	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—C3—glaucoma	5.05e-06	0.000392	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—GSTT1—glaucoma	4.89e-06	0.000379	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—PTGS2—glaucoma	4.76e-06	0.000369	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—NGF—glaucoma	4.72e-06	0.000366	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—APOE—glaucoma	4.71e-06	0.000365	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—CAV1—glaucoma	4.66e-06	0.000361	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—C3—glaucoma	4.49e-06	0.000348	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—FN1—glaucoma	4.44e-06	0.000344	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—BAD—glaucoma	4.38e-06	0.00034	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—NOS3—glaucoma	4.25e-06	0.000329	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—APOE—glaucoma	4.18e-06	0.000324	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CAV1—glaucoma	4.14e-06	0.000321	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	3.94e-06	0.000306	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—FN1—glaucoma	3.94e-06	0.000305	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—ABCA1—glaucoma	3.9e-06	0.000302	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CYP1B1—glaucoma	3.9e-06	0.000302	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—BAD—glaucoma	3.89e-06	0.000302	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—CDKN1B—glaucoma	3.68e-06	0.000285	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—NOS3—glaucoma	3.53e-06	0.000273	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—MMP9—glaucoma	3.41e-06	0.000264	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—NOS3—glaucoma	3.13e-06	0.000243	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—GSTM1—glaucoma	3.12e-06	0.000242	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—VEGFA—glaucoma	3.06e-06	0.000237	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—CDKN1B—glaucoma	3.05e-06	0.000237	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—MMP9—glaucoma	2.83e-06	0.000219	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—MTHFR—glaucoma	2.75e-06	0.000213	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CDKN1B—glaucoma	2.71e-06	0.00021	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—APOE—glaucoma	2.56e-06	0.000199	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CAV1—glaucoma	2.54e-06	0.000197	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—VEGFA—glaucoma	2.54e-06	0.000197	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—MMP9—glaucoma	2.51e-06	0.000195	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—TP53—glaucoma	2.31e-06	0.000179	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—VEGFA—glaucoma	2.26e-06	0.000175	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—NOS3—glaucoma	1.92e-06	0.000149	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—TP53—glaucoma	1.92e-06	0.000149	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—PTGS2—glaucoma	1.76e-06	0.000136	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—TP53—glaucoma	1.7e-06	0.000132	CbGpPWpGaD
